Abdominal pain is common and persistent in patients with IBD. Available anti-inflammatory treatments often fail to relieve pain despite disease remission. Cannabinoid receptor agonists have shown efficacy in visceral pain, but development has been limited by psychotropic effects mediated by the cannabinoid receptor type 1. Olorinab is a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 (CB2 receptor). Herein is an overview of preclinical efficacy, clinical safety, and pharmacokinetics (PK) data from early studies.